License Agreement Terms. The parties intend to enter into a License Agreement prior to initiation of Step 2 with respect to the product formulation(s) developed by Shire hereunder, and following the execution of this Agreement shall negotiate the terms thereof in good faith. Set forth in Schedule 1 is a summary of the principal financial terms of the License Agreement, for which certain of the Shire Technology will be considered to develop product formulations. The License Agreement shall contain such other terms and conditions as may be usual and customary in such transactions and otherwise as may be mutually agreed upon by the parties.
License Agreement Terms. Product CPP-1X/sul, a product including both eflornithine and sulindac as active ingredients (each, an "Active Ingredient"), together as the sole active ingredients or both together in combination with additional active ingredients. For clarity, “Product” includes any product configuration in which the Active Ingredients are packaged for concurrent administration, whether as a single capsule or multiple capsules. Field Treatment, prevention and diagnosis of human diseases and conditions Territory North America Additional Definitions The following definitions are intended for guidance in negotiations only and will be further refined in the License Agreement.
License Agreement Terms. The License Agreement shall include, among other terms and conditions that are customarily included in licensing arrangements between nonprofit academic institutions and for-profit companies, the following terms, but not necessarily limited to the exact language set forth below. The parties agree to work in good faith to have the provisions of the License Agreement not specifically covered by the Agreement be substantially in accordance with CSMC’s standard form of License Agreement, a copy of which is attached hereto as Exhibit B.
License Agreement Terms. It is understood and agreed that the foregoing provisions may be revised as a result of the negotiation of the KHK Agreement Amendment. The foregoing provisions may also be modified upon mutual agreement of the Parties.
License Agreement Terms. Commercial License Agreement to be attached once finalized between parties under terms and conditions to be negotiated in good faith by the Parties within sixty (60) days of the Effective Date of this Agreement. Confidential Treatment Requested by Lightlake Therapeutics Inc. IRS Employer Identification No. 40-0000000 Confidential treatment requested with respect to certain portions hereof denoted with “*** REDACTED ***” AMENDMENT NO. 1 TO THE MATERIAL TRANSFER, OPTION AND RESEARCH LICENSE AGREEMENT EFFECTIVE AS OF DECEMBER 1, 2014
License Agreement Terms. This is a license to run SENTRYWIRE offerings that may be included with the System or purchased to be installed on your Computer System. The Software or, Software with System, is provided to Customer subject to the technical specifications and limitations as defined in the software quotation for which a purchase order is placed and per the following terms and conditions which define what Customer can and cannot do with the Software or Software and System, as well as limitations on warranties and remedies. Although SENTRYWIRE has used reasonable efforts to accurately illustrate and describe its products, such illustrations and descriptions are for the sole purpose of software product identification and do not express or imply a warranty or affirmation of fact, of any kind, or a warranty or affirmation of fact that the products will conform to their respective illustrations or descriptions. All products are sold "as is" and SENTRYWIRE expressly disclaims any warranty or affirmation of fact, express or implied. In addition, SENTRYWIRE expressly disclaims any liability related to product misuse, improper product selection, product recommendation, or product misapplication. The terms and conditions in SENTRYWIRE forms, acknowledgments, quotations, invoices, catalogues, and websites and this license agreement constitute the entire and exclusive agreement between customer and SENTRYWIRE.
License Agreement Terms. (a) Either party may disclose Confidential Information with the prior written consent of the Disclosing Party or to the extent such disclosure is reasonably necessary in the following situations: (i) prosecuting or defending litigation; (ii) complying with applicable laws and regulations, including regulations promulgated by securities exchanges; (iii) complying with a valid order of a court of competent jurisdiction or other Governmental Entity; (iv) for regulatory, tax or customs purposes; (v) for audit purposes, provided that each recipient of Confidential Information must be bound by customary obligations of confidentiality and non-use prior to any such disclosure; (vi) disclosure to its Affiliates and Representatives on a need-to-know basis, provided that each recipient of Confidential Information must be bound by customary obligations of confidentiality and non-use prior to any such disclosure; (vii) disclosure to its actual or potential investors and co-investors, and other sources of funding, including debt financing, or potential partners, collaborators or acquirers, and their respective accountants, financial advisors and other professional representatives, provided, that such disclosure shall be made only to the extent customarily required to consummate such investment, financing transaction partnership, collaboration or acquisition and that each recipient
License Agreement Terms. Notwithstanding the foregoing, in the event the confidentiality and non-use terms of the License Agreement are more stringent than those set forth in this Article 7, then the Buyer agrees to be bound by such more stringent terms in respect of Confidential Information (as defined in the License Agreement) of Licensee received hereunder by the Buyer. Section 7.4
